Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes

Abstract

Besifloxacin acts as an anti-inflammatory agent in monocytes in vitro; this attribute may enhance its efficacy in ocular infections with an inflammatory component and warrants further investigation.

Anti-inflammatory effects of garenoxacin on IL-8 production and ERK1/2 activation induced by lipopolysaccharides in A549 and THP-1 cells

“…In addition, anti-inflammatory effects of quinolones, such as moxifloxacin (Araujo et al, 2002), gatifloxacin (Takeyama et al, 2007), ciprofloxacin (Kaji et al, 2008), and besifloxacin (Zhang and Ward, 2008), have also been reported. In Table 1, we list several reports about inhibitory effects of antibiotic on IL-8 production induced by stimuli in vitro.…”

Comparative In Vitro Susceptibility of Besifloxacin and Seven Comparators Against Ciprofloxacin- and Methicillin-Susceptible/Nonsusceptible Staphylococci

“…It is a sterile solution containing the equivalent of 6 mg/mL of besifloxacin and 0.01% benzalkonium chloride (BAK). [13][14][15] Currently, besifloxacin is approved in the United States and Canada for treatment of bacterial conjunctivitis due to susceptible isolates of Haemophilus influenzae, Streptococcus pneumoniae and other streptococci, Moraxella lacunata, and common species of Corynebacterium sp., as well as susceptible species of Staphylococcus aureus and Coagulase-negative staphylococci. 16 Similar to current fluoroquinolones, besifloxacin inhibits bacterial enzymes DNA gyrase and topoisomerase IV, which are essential for DNA repair, replication, transcription, and partitioning.…”

Scanning Electron Microscopy Visualization of Methicillin-Resistant Staphylococcus aureus After Contact With Gatifloxacin With and Without Preservative

“…Furthermore, when MRSA is resistant to gatifl oxacin or moxifl oxacin, that resistance appears to be reliably carried over to besifl oxacin as well. [14][15][16][17][18] Unlike systemic antibiotics, topical antibiotics are delivered to the eye suspended in a vehicle of preservatives, osmotic agents, and buffers. These excipients are delivered concurrently to the site of infection along with the antibiotic.…”